SeqOnce Biosciences – Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel

CARLSBAD, Calif., July 1, 2025 /PRNewswire/ – SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles Panel A.

“This expansion of our best-in-class RT-qPCR assays for our customers ensures that we can effectively partner throughout their pathogen analysis, from the earliest development stages to clinical research to screening patient samples, where working with multiplex qPCR kits is needed,” said SeqOnce CEO Chris Angermayer.

“We are committed to constantly improving and innovating our offerings to keep pace with the evolving field of Infectious Disease Research & CLIA Testing. Whatever we can do to help keep our environment and community safe by providing genomic tools for those who need them, we will do.”

SeqOnce’s Measles Panel A was developed in response to the increase in measles cases in the United States. The panel is compatible with Bio-Rad, Roche, and ABI qPCR systems. The assay has been specially formulated to detect the D8 genotype responsible for the recent outbreak in the U.S., while also detecting all known circulating measles viruses.

“Our approach to product development involves talking to our customers about what they need based on trends in the marketplace,” said SeqOnce Chief Science Officer Joseph Dunham.

“Once we see a need we can solve, we get to work using our bioinformatic tools to design the panels that work with our enzymes, fluorophores, and buffers. Using this approach allows us to develop high-quality products for our customers that also integrate with our existing product lines.”

SeqOnce’s product portfolio includes multiplex qPCR assays for Respiratory Diseases, Women’s Health, and Antibiotic Resistance.

👉 To learn more, visit our website at www.seqonce.com